Carcinoma, Medullary - 25 Studies Found
Recruiting |
: A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma :
|
Not yet recruiting |
: Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors :
|
Recruiting |
: Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer :
|
Completed |
: Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma :
|
Completed |
: Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors :
|
Active, not recruiting |
: Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors :
|
Completed |
: Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer :
|
Completed |
: Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer :
|
Completed |
: Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu :
|